Mereo BioPharma Group GAAP EPS of -$0.02 in-line

seekingalpha
12 Nov 2024
  • Mereo BioPharma Group press release (NASDAQ:MREO): Q3 GAAP EPS of -$0.02 in-line.
  • The company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the company believes will provide runway into 2027, through multiple key inflection points.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10